Abstract
Among the red cell membrane disorders, hereditary spherocytosis (HS) is one of the most common causes of inherited hemolytic anemia. HS results from the deficiency or dysfunction of red blood cell membrane proteins, such as α spectrin, β spectrin, ankyrin, anion channel protein (Band-3 protein), protein 4.1 and protein 4.2. Conventionally, HS diagnosis is established through a series of tests, which include spherocytes identification in peripheral smear, reticulocyte count, osmotic fragility, etc. Currently, different hematological analyzers provide erythrocyte indicators that estimate the presence of spherocytes and correlate that with HS, which can be useful for disease screening. The most traditional method is the osmotic fragility (OF) test, which is labor-intensive and time-consuming to perform and presents low sensitivity and specificity values. Thus, new methods have been developed for HS diagnosis, such as flow cytometry. Current guidelines recommend the use of flow cytometry as a screening test for HS diagnosis using the eosin-5′-maleimide (EMA) binding test. Thus, HS diagnosis is the result of a collaboration between clinicians and laboratories, who should take into account the family history and the exclusion of other causes of secondary spherocytosis.
Author contributions: The author has accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Tse WT, Lux SE. Red Blood cell membrane disorders. Br J Haematol 1999;104:2–13.10.1111/j.1365-2141.1999.01130.xSearch in Google Scholar PubMed
2. Eber SW, Pekrun A, Neufeldt A, Schröter W. Prevalence of increased osmotic fragility of erythrocytes in German blood donors: screening using a modified glycerol lysis test. Ann Hematol 1992;64:88–92.10.1007/BF01715351Search in Google Scholar PubMed
3. Mariani M, Barcellini W, Vercellati C, Marcello AP, Fermo E, Pedotti P, et al. Clinical and hematologic features of 300 patients affected by hereditary spherocytosis grouped according to the type of the membrane protein defect. Haematologica 2008;93:1310–7.10.3324/haematol.12546Search in Google Scholar PubMed
4. Parpart AK, Lorenz PB, Parpart ER, Gregg JR, Chase AM. The osmotic resistance (fragility) of human red cells. J Clin Invest 1947;26:636–40.10.1172/JCI101847Search in Google Scholar PubMed PubMed Central
5. Zanella A, Izzo C, Rebulla P, Zanuso F, Perroni L, Sirchia G. Acidified glycerol lysis test: a screening test for spherocytosis. Br J Haematol 1980;45:481–6.10.1111/j.1365-2141.1980.tb07167.xSearch in Google Scholar PubMed
6. Crisp RL, Solari L, Vota D, García E, Miguez G, Chamorro ME, et al. A prospective study to assess the predictive value for hereditary spherocytosis using five laboratory tests (cryohemolysis test, eosin-5′-maleimide flow cytometry, osmotic fragility test, autohemolysis test, and SDS-PAGE) on 50 hereditary spherocytosis families in Argentina. Ann Hematol 2011;90:625–34.10.1007/s00277-010-1112-0Search in Google Scholar PubMed
7. Iolascon A, Avvisati RA. Genotype/phenotype correlation in hereditary spherocytosis. Haematologica 2008;93:1283–8.10.3324/haematol.13344Search in Google Scholar PubMed
8. Oliveira RA. Hemograma: como fazer e interpretar. São Paulo: Livraria Médica Paulista Editora, 2007.Search in Google Scholar
9. Kutter D. Strategy for screening for hereditary spherocytosis. J Chinese Clin Med 2007;2:266–72.Search in Google Scholar
10. King MJ, Garçon L, Hoyer JD, Iolascon A, Picard V, Stewart G, et al. ICSH guidelines for the laboratory diagnosis of nonimmune hereditary red cell membrane disorders. Int J Lab Hematol 2015;37:304–25.10.1111/ijlh.12335Search in Google Scholar PubMed
11. Broséus J, Visomblain B, Guy J, Maynadié M, Girodon F. Evaluation of mean sphered corpuscular volume for predicting hereditary spherocytosis. Int J Lab Hem 2010;32:519–23.10.1111/j.1751-553X.2009.01216.xSearch in Google Scholar PubMed
12. Lazarova E, Pradier O, Cotton F, Gulbis B. Automated reticulocyte parameters for hereditary spherocytosis screening. Ann Hematol 2014;93:1809–18.10.1007/s00277-014-2127-8Search in Google Scholar PubMed
13. Liao L, Deng ZF, Qiu YL, Chen P, Chen WQ, Lin FQ. Values of mean cell volume and mean sphered cell volume can differentiate hereditary spherocytosis and thalassemia. Hematology 2014;19:393–6.10.1179/1607845413Y.0000000149Search in Google Scholar
14. Rooney S, Hoffmann JJ, Cormack OM, McMahon C. Screening and confirmation of hereditary spherocytosis in children using a CELL-DYN Sapphire haematology analyser. Int J Lab Hem 2015;37:98–104.10.1111/ijlh.12245Search in Google Scholar
15. Mullier F, Lainey E, Fenneteau O, Da Costa L, Schillinger F, Bailly N, et al. Additional erythrocytic and reticulocytic parameters helpful for diagnosis of hereditary spherocytosis: results of a multicentre study. Ann Hematol 2011;90:759–68.10.1007/s00277-010-1138-3Search in Google Scholar
16. Bolton-Maggs PH, Stevens RF, Dodd NJ, Lamont G, Tittensor P, King MJ. General Haematology Task Force of the British Committee for Standards in Haematology. Guidelines for the diagnosis and management of hereditary spherocytosis. Br J Haematol 2004;126:455–74.10.1111/j.1365-2141.2004.05052.xSearch in Google Scholar
17. Perrotta S, Gallagher PG, Mohandas N. Hereditary spherocytosis. Lancet 2008;372:1411–26.10.1016/S0140-6736(08)61588-3Search in Google Scholar
18. Bolton-Maggs PH, Langer JC, Iolascon A, Tittensor P, King MJ. General Haematology task force of the British Committee for Standards in Haematology. Guidelines for the diagnosis and management of hereditary spherocytosis-2011 update. Br J Haematol 2012;156:37–49.10.1111/j.1365-2141.2011.08921.xSearch in Google Scholar PubMed
19. Bain BJ, Bates I, Laffan MA. Dacie and lewis practical haematology, 11th ed. London: Elsevier Churchill Livingstone.Search in Google Scholar
20. Stoya G, Gruhn B, Vogelsang H, Baumann E, Linss W. Flow cytometry as a diagnostic tool for hereditary spherocytosis. Acta Haematol 2006;116:186–91.10.1159/000094679Search in Google Scholar PubMed
21. King MJ, Behrens J, Rogers C, Flynn C, Greenwood D, Chambers K. Rapid flow cytometry test for the diagnosis of membrane cytoskeleton-associated haemolytic anaemia. Br J Haematol 2000;111:924–33.Search in Google Scholar
22. Won DI, Suh JS. Flow Cytometric detection of erythrocyte osmotic fragility. Cytometry B Clin Cytom 2009;76:135–41.10.1002/cyto.b.20448Search in Google Scholar PubMed
23. Warang P, Gupta M, Kedar P, Ghosh K, Colah R. Flow cytometric osmotic fragility-an effective screening approach for red cell membranopathies. Cytometry B Clin Cytom 2011;80:186–90.10.1002/cyto.b.20583Search in Google Scholar PubMed
24. Yamamoto A, Saito N, Yamauchi Y, Takeda M, Ueki S, Itoga M, et al. Flow cytometric analysis of red blood cell osmotic fragility. J Lab Autom 2014;19:483–7.10.1177/2211068214532254Search in Google Scholar PubMed
25. Shim YJ, Won DI. Flow Cytometric osmotic fragility testing does reflect the clinical severity of hereditary spherocytosis. Cytometry B Clin Cytom 2014;86:436–43.10.1002/cytob.21143Search in Google Scholar
26. King MJ, Smythe JS, Mushens R. Eosin-5-maleimide binding to band 3 and Rh related proteins forms the basis of a screening test for hereditary spherocytosis. Br J Haematol 2004;124:106–13.10.1046/j.1365-2141.2003.04730.xSearch in Google Scholar PubMed
27. Ciepiela O, Adamowicz-Salach A, Bystrzycka W, Łukasik J, Kotuła I. Mean corpuscular volume of control red blood cells determines the interpretation of eosin-5′-maleimide (EMA) test result in infants aged less than 6 months. Ann Hematol 2015;94:1277–83.10.1007/s00277-015-2377-0Search in Google Scholar PubMed PubMed Central
28. Girodon F, Garçon L, Bergoin E, Largier M, Delaunay J, Fénéant-Thibault M, et al. Usefulness of the eosin-5′-maleimide cytometric method as a first-line screening test for the diagnosis of hereditary spherocytosis: comparison with ektacytometry and protein electrophoresis. Br J Haematol 2008;140:468–70.10.1111/j.1365-2141.2007.06944.xSearch in Google Scholar PubMed
29. Joshi P, Aggarwal A, Jamwal M, Sachdeva MU, Bansal D, Malhotra P, et al. A comparative evaluation of Eosin-5′-maleimide flow cytometry reveals a high diagnostic efficacy for hereditary spherocytosis. Int J Lab Hematol 2016;38:520–6.10.1111/ijlh.12533Search in Google Scholar PubMed
30. Bianchi P, Fermo E, Vercellati C, Marcello AP, Porretti L, Cortelezzi A, et al. Diagnostic power of laboratory tests for hereditary spherocytosis: a comparison study in 150 patients grouped according to molecular and clinical characteristics. Haematologica 2012;97:516–23.10.3324/haematol.2011.052845Search in Google Scholar PubMed PubMed Central
31. King MJ, Telfer P, MacKinnon H, Langabeer L, McMahon C, Darbyshire P, et al. Using the eosin-5-maleimide binding test in the differential diagnosis of hereditary spherocytosis and hereditary pyropoikilocytosis. Cytometry B Clin Cytom 2008;74:244–50.10.1002/cyto.b.20413Search in Google Scholar PubMed
32. Miller WG, Myers GL, Lou Gantzer ML, Kahn SE, Schömbrunner ER, Thienpont LM, et al. Roadmap for harmonization of clinical laboratory measurement procedures. Clin Chem 2011;57: 1108–17.10.3343/lmo.2012.2.1.1Search in Google Scholar
33. Kedar PS, Colah RB, Kulkarni S, Ghosh K, Mohanty D. Experience with eosin-5′-maleimide as a diagnostic tool for red cell membrane cytoskeleton disorders. Clin Lab Haematol 2003;25:373–6.10.1046/j.0141-9854.2003.00557.xSearch in Google Scholar PubMed
34. Ciepiela O, Adamowicz-Salach A, Zdziechowicz I, Kotuła I. Delayed measurement of eosin-5′-maleimide binding may affect the test results of highly hemolyzed samples in vivo and In vitro-a case study. J Pediatr Hematol Oncol 2016;38:e303–6.10.1097/MPH.0000000000000652Search in Google Scholar PubMed
35. Mehra S, Tyagi N, Dorwal P, Pande A, Jain D, Sachdev R, et al. Stability of eosin-5′-maleimide dye used in flow cytometric analysis for red cell membrane disorders. Blood Res 2015;50: 109–12.10.5045/br.2015.50.2.109Search in Google Scholar PubMed PubMed Central
36. Hunt L, Greenwood D, Heimpel H, Noel N, Whiteway A, King MJ. Toward the harmonization of result presentation for the eosin-5′-maleimide binding test in the diagnosis of hereditary spherocytosis. Cytometry B Clin Cytom 2015;88:50–7.10.1002/cytob.21187Search in Google Scholar PubMed
37. Kar R, Mishra P, Pati HP. Evaluation of eosin-5-maleimide flow cytometric test in diagnosis of hereditary spherocytosis. Int J Lab Hematol 2010;32(1 Pt 2):8–16.10.1111/j.1751-553X.2008.01098.xSearch in Google Scholar PubMed
38. Agarwal AM, Liew MA, Nussenzveig RH, Sangle N, Heikal N, Yaish H, et al. Improved harmonization of eosin-5-maleimide binding test across different instruments and age groups. Cytometry B Clin Cytom 2015; doi:10.1002 cyto.b.21326.Search in Google Scholar
39. Mackiewicz G, Bailly F, Favre B, Guy J, Maynadié M, Girodon F. Flow cytometry test for hereditary spherocytosis. Haematologica 2012;97:e47.10.3324/haematol.2012.072660Search in Google Scholar PubMed PubMed Central
40. Park SH, Park CJ, Lee BR, Cho YU, Jang S, Kim N, et al. Comparison study of the eosin-5′-maleimide binding test, flow cytometric osmotic fragility test, and cryohemolysis test in the diagnosis of hereditary spherocytosis. Am J Clin Pathol 2014; 142:474–84.10.1309/AJCPO7V4OGXLIIPPSearch in Google Scholar PubMed
41. Tao YF, Deng ZF, Liao L, Qiu YL, Deng XL, Chen WQ, et al. Evaluation of a flow-cytometric osmotic fragility test for hereditary spherocytosis in chinese patients. Acta Haematol 2015;135:88–93.10.1159/000438738Search in Google Scholar PubMed
©2017 Walter de Gruyter GmbH, Berlin/Boston
